MAGEA3 and non-small cell lung carcinoma: The efficacy of MAGE-A3 as adjuvant therapy was examined in a randomized, double-blind, placebo-controlled MAGRIT phase III trial, showing that adjuvant therapy with the MAGE-A3 did not show the benefit in disease-free survival compared with placebo in patients with resected MAGE-A3-positive NSCLC.